These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 16880939

  • 1. Chemogenomics: drug discovery's panacea?
    Jacoby E.
    Mol Biosyst; 2006 May; 2(5):218-20. PubMed ID: 16880939
    [Abstract] [Full Text] [Related]

  • 2. Discovery on Target 2006 - CHI's fourth annual event. Chemogenomics: small molecules as biological probes.
    Murphy M.
    IDrugs; 2007 Jan; 10(1):30-2. PubMed ID: 17187311
    [No Abstract] [Full Text] [Related]

  • 3. Chemogenomics approaches to novel target discovery.
    Gaither LA.
    Expert Rev Proteomics; 2007 Jun; 4(3):411-9. PubMed ID: 17552925
    [Abstract] [Full Text] [Related]

  • 4. Current parallel chemistry principles and practice: application to the discovery of biologically active molecules.
    Edwards PJ.
    Curr Opin Drug Discov Devel; 2009 Nov; 12(6):899-914. PubMed ID: 19894197
    [Abstract] [Full Text] [Related]

  • 5. Exploring the chemogenomic knowledge space with annotated chemical libraries.
    Savchuk NP, Balakin KV, Tkachenko SE.
    Curr Opin Chem Biol; 2004 Aug; 8(4):412-7. PubMed ID: 15288252
    [Abstract] [Full Text] [Related]

  • 6. Chemogenomics: structuring the drug discovery process to gene families.
    Harris CJ, Stevens AP.
    Drug Discov Today; 2006 Oct; 11(19-20):880-8. PubMed ID: 16997137
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Advance in the research and discovery of novel drugs based on chemogenomics].
    He BK, Ma ZC, Wang YG, Gao Y.
    Yao Xue Xue Bao; 2008 Nov; 43(11):1077-81. PubMed ID: 19239023
    [Abstract] [Full Text] [Related]

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 10. Microbial genomics and drug discovery: exploring innovative routes of drug discovery in the postgenomic era.
    Dougherty TJ, Miller PF.
    IDrugs; 2006 Jun; 9(6):420-2. PubMed ID: 16752312
    [Abstract] [Full Text] [Related]

  • 11. Combinatorial informatics in the post-genomics ERA.
    Agrafiotis DK, Lobanov VS, Salemme FR.
    Nat Rev Drug Discov; 2002 May; 1(5):337-46. PubMed ID: 12120409
    [Abstract] [Full Text] [Related]

  • 12. Structure-directed combinatorial library design.
    Zhou JZ.
    Curr Opin Chem Biol; 2008 Jun; 12(3):379-85. PubMed ID: 18328830
    [Abstract] [Full Text] [Related]

  • 13. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases.
    Nidhi, Glick M, Davies JW, Jenkins JL.
    J Chem Inf Model; 2006 Jun; 46(3):1124-33. PubMed ID: 16711732
    [Abstract] [Full Text] [Related]

  • 14. Diversity-oriented synthesis; a spectrum of approaches and results.
    Spandl RJ, Bender A, Spring DR.
    Org Biomol Chem; 2008 Apr 07; 6(7):1149-58. PubMed ID: 18362950
    [Abstract] [Full Text] [Related]

  • 15. The use of chemical design tools to transform proteomics data into drug candidates.
    Dean PM, Zanders ED.
    Biotechniques; 2002 Mar 07; Suppl():28-33. PubMed ID: 11906004
    [Abstract] [Full Text] [Related]

  • 16. Learning from the data: mining of large high-throughput screening databases.
    Yan SF, King FJ, He Y, Caldwell JS, Zhou Y.
    J Chem Inf Model; 2006 Mar 07; 46(6):2381-95. PubMed ID: 17125181
    [Abstract] [Full Text] [Related]

  • 17. Chemogenomics in drug discovery.
    Kubinyi H.
    Ernst Schering Res Found Workshop; 2006 Mar 07; (58):1-19. PubMed ID: 16708995
    [Abstract] [Full Text] [Related]

  • 18. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era.
    Frye SV.
    Chem Biol; 1999 Jan 07; 6(1):R3-7. PubMed ID: 9889153
    [Abstract] [Full Text] [Related]

  • 19. Hit and lead generation: beyond high-throughput screening.
    Bleicher KH, Böhm HJ, Müller K, Alanine AI.
    Nat Rev Drug Discov; 2003 May 07; 2(5):369-78. PubMed ID: 12750740
    [Abstract] [Full Text] [Related]

  • 20. When poor solubility becomes an issue: from early stage to proof of concept.
    Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H.
    Eur J Pharm Sci; 2007 Aug 07; 31(5):249-61. PubMed ID: 17616376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.